Key facts
- Sesame Therapeutics’s last known valuation is $59.0M (Jul 2025).
- It has raised $28.3M; the latest was Early Stage VC ($19.0M) in Jul 2025.
- Notable investors include Qiming Venture Partners, Nextech Invest.
- Status: Privately Held (backing).
Investors
2- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for Sesame Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for Sesame Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Sesame Therapeutics
Operator of a precision oncology company intended to offer cancer medicines with wide therapeutic windows. The company transforms highly validated but pan-lethal targets into selective therapies by engineering selective lethality within cancer-specific protein neighborhoods and leveraging inherent molecular proximity to discover small molecules, enabling health care institutions to treat cancer effectively.
- Sector
- Healthcare
- HQ
- Plymouth, MA, United States
- Founded
- 2023
- Ownership
- Privately Held (backing)
Sesame Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Sesame Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Sesame Therapeutics in its N-PORT filings yet. We sweep new filings monthly.